Interim Results for 6 months to 31 December 2011

Bioventix plc                                 

           INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2011           

Bioventix plc (BVXP) ("Bioventix" or "the Company"), a UK company specialising
in the development and commercial supply of high-affinity monoclonal antibodies
for applications in clinical diagnostics, announces its unaudited interim
financial results for the six-month period ending 31 December 2011.

Highlights

  * Revenues have grown by 46% compared with the six months to 31 December 2010
   
  * Profit after tax increased by 83% compared with the six months to 31
    December 2010
   
  * Cash balances of £1.94m at 31 December 2011 (£1.49m at 31 December 2010)
   
  * Interim dividend declared of 4.84p (2011: 4.4p)
   
CHAIRMAN AND CHIEF EXECUTIVE'S STATEMENT

We are delighted to report the results for the half-year ended 31 December
2011. Revenues for the half-year period of £1,298,428 (2010:£890,256) have
grown by 46%. The growth in sales has arisen from a continued increase in the
supply of purified antibody products to our customers for research and
development ("R&D") and commercial use and a higher level of royalties from
established antibody products. Profit before tax of £873,732 (2010:£493,511)
has increased through a combination of the growth in revenues and controlling
of the cost base of the company. Cash balances at 31 December 2011 were £
1,940,437 (2010: £1,494,710).

We have previously reported our optimism relating to our vitamin D activities
and a leading antibody known as vitD3.5H10. This has now moved into large scale
manufacturing at the company in order to supply quantities of antibody required
for our customers' own R&D use. Revenue from the supply of this product has
continued to grow significantly during the period. At the end of the reporting
period, no significant commercial vitamin D assays based on vitD3.5H10 were in
the market. However, the Directors remain optimistic about the future value of
this particular antibody and a small number of licensing deals have now been
concluded with major multinational diagnostics companies.

In line with our strategy to develop new valuable antibodies, the company has
continued with its own R&D activities aimed at augmenting the pipeline of
future antibodies for commercialisation at Bioventix's customers.

As we have stressed before, the continued success of the company is based on
the ability to create and manufacture unique antibodies in a global and
competitive environment. This is made possible by the creativity and focus of
the scientists and support staff at the company and we would like to thank them
for their efforts which have underpinned our success.

The Board of Bioventix is pleased to declare an interim dividend of 4.84p
(2010: 4.4p) per Ordinary share. The shares will be marked ex-dividend on 21
March 2012 and the dividend will be paid on 28 March 2012 to shareholders on
the register at close of business on 23 March 2012.

SpringHill BioVentures (SBV) continues to hold a substantial majority stake in
the company. The board believes that SBV will distribute its shares to SBV's
underlying shareholders as part of its fund exit during the course of 2012.

P J Harrison

Chief Executive Officer

I J Nicholson

Non-Executive Chairman

                                 BIOVENTIX PLC                                 

                            PROFIT AND LOSS ACCOUNT                            

                for the six month period ended 31 December 2011                

                                                      Six months     Six months
                                                                               
                                                           ended          ended
                                                                               
                                                     31 Dec 2011    31 Dec 2010
                                                                               
                                                               £              £
                                                                               
TURNOVER                                               1,298,428        890,256
                                                                               
Cost of sales                                           (73,475)       (69,369)
                                                                               
GROSS PROFIT                                           1,224,953        820,887
                                                                               
Administrative expenses                                (356,451)      (328,549)
                                                                               
OPERATING PROFIT                                         868,502        492,338
                                                                               
Interest receivable                                        5,230          1,173
                                                                               
Interest payable                                               -              -
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION            873,732        493,511
                                                                               
Tax on profit on ordinary activities                   (173,647)      (111,201)
                                                                               
PROFIT FOR THE FINANCIAL PERIOD                          700,085        382,310
                                                                               


                                 BIOVENTIX PLC                                 

                                 BALANCE SHEET                                 

                            as at 31 December 2011                             

                                               31 Dec 2011       31 Dec 2010
                                                                            
                                                         £                 £
                                                                            
FIXED ASSETS                                                                
                                                                            
Intangible fixed assets                             40,000            60,000
                                                                            
Tangible fixed assets                              448,419           458,720
                                                                            
                                                   488,419           518,720
                                                                            
CURRENT ASSETS                                                              
                                                                            
Stocks                                             111,507           128,239
                                                                            
Debtors                                            755,984           550,310
                                                                            
Cash at bank and in hand                         1,940,437         1,494,710
                                                                            
                                                 2,807,928         2,173,259
                                                                            
CREDITORS:amounts falling due within one         (243,017)         (288,090)
year                                                                        
                                                                            
NET CURRENT ASSETS                               2,564,911         1,885,169
                                                                            
TOTAL ASSETS LESS CURRENT LIABILITIES            3,053,330         2,403,889
                                                                            
PROVISIONS FOR LIABILITIES                                                  
                                                                            
Deferred Tax                                       (7,527)           (7,528)
                                                                            
NET ASSETS                                       3,045,803         2,396,361
                                                                            
CAPITAL AND RESERVES                                                        
                                                                            
Called up share capital                            251,269           251,269
                                                                            
Capital redemption reserve                           1,231             1,231
                                                                            
Profit and loss account                          2,793,303         2,143,861
                                                                            
SHAREHOLDERS' FUNDS                              3,045,803         2,396,361

BIOVENTIX PLC

Notes to the financial information

 1. While the interim financial information has been prepared using the
    company's accounting policies and in accordance with UK GAAP, the
    announcement does not itself contain sufficient information to comply with
    UK GAAP.
   
 2. This interim financial statement has not been audited or reviewed by the
    auditors.
   
The Directors of Bioventix plc accept responsibility for this announcement.

For further information, please contact:

Bioventix plc

Peter Harrison

Tel: [phone]

Keith, Bayley, Rogers & Co. Limited

David Coffman

Tel: [phone]